GTx
At GTx, They focus on the development of small molecules that selectively modulate the effects of certain hormones produced by the body.
Launch date
Market cap
-
Enterprise valuation
€73—109m (Dealroom.co estimates Aug 2003.)
Memphis Tennessee (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$20.0m | Series E | ||
N/A | N/A | IPO | |
N/A | $30.0m | Debt | |
N/A | $30.0m | Early VC | |
$21.3m | Post IPO Equity | ||
$43.4m | Post IPO Equity | ||
$48.5m | Post IPO Equity | ||
Total Funding | €45.5m |
Related Content
Recent News about GTx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.